Evidence map›Paper›PMID 21879898›Full record

ArticleThe New England journal of medicine2011

A functional element necessary for fetal hemoglobin silencing.

Vijay G Sankaran, Jian Xu, Rachel Byron, Harvey A Greisman, Chris Fisher, David J Weatherall, Daniel E Sabath, Mark Groudine, Stuart H Orkin, Anuja Premawardhena and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The New England journal of medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 2 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 2 syntheses or guidelines pooled it, 184 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β-Thalassemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. LRF Promotes Indirectly Advantageous Chromatin Conformation viaInternational journal of molecular sciences · 2022
    Article
  15. Article
  16. Article
  17. CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease.Molecular therapy. Methods & clinical development · 2021
    Review
  18. Article
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 4 countries.

Vijay G SankaranDepartment of Medicine, Children's Hospital Boston, Boston, MA 02115, USA. sankaran@broadinstitute.org
Jian Xu
Rachel Byron
Harvey A Greisman
Chris Fisher
David J Weatherall
Daniel E Sabath
Mark Groudine
Stuart H Orkin
Anuja Premawardhena
M A Bender
Boston Children's Hospital · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAMRC Weatherall Institute of Molecular Medicine · GBUniversity of Washington · USDana-Farber Cancer Institute · USFred Hutch Cancer Center · USUniversity of Kelaniya · LK

Funding

MAINTENANCE OF GENE EXPRESSION IN THE RED CELL LINEAGER01HL065440 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GROUDINE, MARK T · 2000 to 2018
$12.4M
FUNCTION OF HUMAN &MOUSE B GLOBIN LOCUS CONTROL REGIONSR37DK044746 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GROUDINE, MARK T · 1997 to 2016
$12.3M
MOLECULAR ANALYSIS OF NORMAL AND TYHALASSEMIC DNAR01HL032259 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI ORKIN, STUART H · 1985 to 2022
$8.8M
FUNCTION OF THE HUMAN B-GLOBIN LOCUS CONTROL REGION-LCRR01DK044746 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GROUDINE, MARK T · 1992 to 1996
–
NHLBI NIH HHS HL032259NHLBI NIH HHS R01 HL032259NHLBI NIH HHS R01 HL065440NIDDK NIH HHS DK44746NIDDK NIH HHS R37 DK044746Wellcome Trust
6 · The paper itself

Abstract

backgroundAn improved understanding of the regulation of the fetal hemoglobin genes holds promise for the development of targeted therapeutic approaches for fetal hemoglobin induction in the β-hemoglobinopathies. Although recent studies have uncovered trans-acting factors necessary for this regulation, limited insight has been gained into the cis-regulatory elements involved.

methodsWe identified three families with unusual patterns of hemoglobin expression, suggestive of deletions in the locus of the β-globin gene (β-globin locus). We performed array comparative genomic hybridization to map these deletions and confirmed breakpoints by means of polymerase-chain-reaction assays and DNA sequencing. We compared these deletions, along with previously mapped deletions, and studied the trans-acting factors binding to these sites in the β-globin locus by using chromatin immunoprecipitation.

resultsWe found a new (δβ)(0)-thalassemia deletion and a rare hereditary persistence of fetal hemoglobin deletion with identical downstream breakpoints. Comparison of the two deletions resulted in the identification of a small intergenic region required for γ-globin (fetal hemoglobin) gene silencing. We mapped a Kurdish β(0)-thalassemia deletion, which retains the required intergenic region, deletes other surrounding sequences, and maintains fetal hemoglobin silencing. By comparing these deletions and other previously mapped deletions, we elucidated a 3.5-kb intergenic region near the 5' end of the δ-globin gene that is necessary for γ-globin silencing. We found that a critical fetal hemoglobin silencing factor, BCL11A, and its partners bind within this region in the chromatin of adult erythroid cells.

conclusionsBy studying three families with unusual deletions in the β-globin locus, we identified an intergenic region near the δ-globin gene that is necessary for fetal hemoglobin silencing. (Funded by the National Institutes of Health and others.).

Indexed as

Gene Expression RegulationAdultbeta-Globinsbeta-ThalassemiaChildChromatin Assembly and DisassemblyFemaleFetal HemoglobinGene DeletionGene SilencingHumansMalePedigreePhenotypeTrans-Activatorsbeta-GlobinsFetal HemoglobinTrans-Activators

Identifiers

PMID21879898
PMCPMC3174767
OpenAlexW2170482856

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.